Our argument is strongly supported by our findings showing prominent nuclear YAP expression in ALK‐TKI‐resistant tumors compared with pretreatment tumors in ALK‐rearranged NSCLC patients (Fig 6). The gene discussed is ALK; the disease is non-small cell lung carcinoma.